– New findings to be presented at the 2025 European Association for the Study of the Liver (EASL) Congress continue to demonstrate the effectiveness of Livdelzi (seladelpar) in reducing pruritus ...

Primary biliary cholangitis (PBC) is an autoimmune disorder that leads to the destruction of bile ducts within the liver. As more bile ducts become lost and damaged, bile acids build up within the ...

IQIRVO ® (elafibranor) is the first new medicine approved in nearly a decade for the treatment of rare cholestatic liver disease Primary Biliary Cholangitis ... tolerate UDCA. 1 Ipsen Logo ...

IQIRVO ® (elafibranor) is the first new ... of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in ...

The venue in Vancouver will be the PWHL's first ... a pretty big step for us." The PWHL is rumored to be looking at Seattle for their second expansion market. There would be no primary venue ...

Ipsen has announced that its Iqirvo (elafibranor) tablets have been accepted by the Scottish Medicines Consortium (SMC) to treat adults with the rare cholestatic liver disease primary biliary ...

Ipsen has been given accelerated approval by the FDA for Iqirvo, which becomes the first dual PPAR alpha/delta agonist for rare cholestatic liver disease primary biliary cholangitis (PBC).

1 Elafibranor, a 'first-in-class' molecule marketed and ... trademark Iqirvo® since June 2024 for the treatment of Primary Biliary Cholangitis (PBC), was developed by GENFIT, from initial ...

Elafibranor, a 'first-in-class' molecule marketed and commercialized in the United States, the European Union and the UK by Ipsen under the trademark Iqirvo® since June 2024 for the treatment of ...

Endoscopic ultrasound–guided rendezvous and precut sphincterotomy are both effective salvage techniques for patients with ...

Here’s the kicker: I’m one of 47,583 people in Singapore certified in first aid, including cardiopulmonary ... low at 58 per cent. That is a step up from 2020, when just 50 per cent had ...

At the start of the year, there had been no new therapies for rare cholestatic liver disease primary biliary cholangitis (PBC ... PBC could be worth $1.5 billion or more per year.